中国药业2011，Vol.20Issue(17)：18-19,2.
阿司匹林铝镁合剂对冠心病患者抗血小板聚集的有效性与安全性评价
Efficacy and Safety of Aspirin Aluminum-Magnesium Mixture in Patients with Acute Coronary Syndrome Treated by Anti-Platelet Aggregation Therapy
张邑 1杜春丽 1刘小燕 1成力 1周音频 1何作云 1于学军1
作者信息
- 1. 第三军医大学新桥医院心内科,重庆,400037
- 折叠
摘要
Abstract
Objective To investigate the safety and efficacy of Aspirin Aluminum -Magnesium Mixture (containing aspirin 81 mg, aluminum glycinate 11 mg and heavy magnesium carhonate 22 mg) in the patients with acute coronary syndrome (ACS) treated by anti - platelet aggregation therapy. Methods The single - blind, randomized, parallel - controlled clinical study method was used to compare the safety and efficacy of Aspirin Aluminum - Magnesium Mixture(group A) and Aspirin Enteric - Coated Tablets(group B) in treating the patients with ACS for 12 weeks. Results The platelet aggregation rate before treatment in the two groups was significantly higher than that in normal person( P ＜ 0. 01), and after treatment, which was significantly decreased( P ＜ 0. 05 ), showing no significant difference between the two groups ( P ＞ 0. 05). But the orcurrence rate of gastrointestinal adverse reactions during the trial process in the group A was significantly lower than that in the group B( P ＜ 0. 05). Conclusion The safety of Aspirin Aluminum - Magnesium Mixture is superior to that of Aspirin Enteric - Coated Tablets with the similar anti - platelet aggregation effect.关键词
阿司匹林铝镁合剂/冠心病/抗血小板聚集/有效性/安全性Key words
Aspirin Aluminum - Magnesium Mixture/ ACS/ anti - platelet aggregation/ safety/ effectiveness分类
医药卫生引用本文复制引用
张邑,杜春丽,刘小燕,成力,周音频,何作云,于学军..阿司匹林铝镁合剂对冠心病患者抗血小板聚集的有效性与安全性评价[J].中国药业,2011,20(17):18-19,2.
